The pharmacology of selegiline

International Review of Neurobiology

Volumn 100, Issue , 2011, Pages 65-84

  Magyar, Kálmán ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Antiapoptotic effect of selegiline; Future perspectives of selegiline; Metabolic studies; Multiplicity of monoamine oxidase; Pharmacokinetics; Selective inhibition of MAO B; Structure activity relationship studies

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOL METHYLTRANSFERASE; CLORGYLINE; DEPRENYL N OXIDE; DOPAMINE; HYDRAZINE DERIVATIVE; IPRONIAZID; N (1 INDENYL) N METHYL N PROPARGYLAMINE; NORSELEGILINE; PHENELZINE; PHENETHYLAMINE; PROADIFEN; RASAGILINE; SELEGILINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

APOPTOSIS; AREA UNDER THE CURVE; BOOK; CELL ADHESION; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SPECIFICITY; HUMAN; IC 50; NEUROPROTECTION; NONHUMAN; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 80053467982     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386467-3.00004-2     Document Type: Chapter

References (96)

1. Azzaro A.J., Ziemniak J., Kemper E., Campbell B.J., VanDenBerg C. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6mg/24 h): a comparison with oral selegiline capsules. J. Clin. Pharmacol. 2007, 47:1256-1267.
2. (R) (selegiline hydrochloride). Am. J. Ther. 1996, 3:298-313.
3. Barrett J.S., Hochadel T.J., Morales R.J., Rohatagi S., DeWitt K.E., Watson S.K., DiSanto A.R. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. Am. J. Ther. 1996, 3:688-698.
4. Birkmayer W., Riederer P., Youdim M.B., Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J. Neural Transm. 1975, 36:303-326.
5. Birkmayer W., Riederer P., Ambrozi L., Youdim M.B. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1977, 1:439-443.
6. Birkmayer W., Knoll J., Riederer P., Youdim M.B., Hars V., Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J. Neural Transm. 1985, 64:113-127.
7. Blackwell B., Marley E., Price J., Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br. J. Psychiatry 1967, 113:349-365.
8. Blaschko H. The natural history of amine oxidases. Rev. Physiol. Biochem. Pharmacol. 1974, 70:83-148.
9. Carrillo M.C., Kanai S., Nokubo M., Kitani K. (-)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 1991, 48:517-521.
10. Chen K., Cases O., Rebrin I., Wu W., Gallaher T.K., Seif I., Shih J.C. Forebrain-specific expression of monoamine oxidase A reduces neurotransmitter levels, restores the brain structure, and rescues aggressive behavior in monoamine oxidase A-deficient mice. J. Biol. Chem. 2007, 282:115-123.
11. Choi W.S., Abel G., Klintworth H., Flavell R.A., Xia Z. JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death. J. Neuropathol. Exp. Neurol. 2010, 69:511-520.
12. Dragoni S., Bellik L., Frosini M., Sgaragli G., Marini S., Gervasi P.G., Valoti M. l-Deprenyl metabolism by the cytochrome P450 system in monkey (Cercopithecus aethiops) liver microsomes. Xenobiotica 2003, 33:181-195.
13. Edmondson D.E., Mattevi A., Binda C., Li M., Hubalek F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 2004, 11:1983-1993.
14. Ekstedt B., Magyar K., Knoll J. Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?. Biochem. Pharmacol. 1979, 28:919-923.
15. Feiger A.D., Rickels K., Rynn M.A., Zimbroff D.L., Robinson D.S. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J. Clin. Psychiatry 2006, 67:1354-1361.
16. Fowler C.J., Tipton K.F. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J. Neurochem. 1982, 38:733-736.
17. Glover V., Gibb C., Sandler M. The role of MAO in MPTP toxicity-a review. J. Neural Transm. Suppl. 1986, 20:65-76.
18. Grace J.M., Kinter M.T., Macdonald T.L. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N, alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 1994, 7:286-290.
19. Haberle D., Magyar K., Szoko E. Determination of the norepinephrine level by high-performance liquid chromatography to assess the protective effect of MAO-B inhibitors against DSP-4 toxicity. J. Chromatogr. Sci. 2002, 40:495-499.
20. Hare M.L. Tyramine oxidase: A new enzyme system in liver. Biochem. J. 1928, 22:968-979.
21. Heinonen E.H., Myllyla V., Sotaniemi K., Lamintausta R., Salonen J.S., Anttila M., Savijarvi M., Kotila M., Rinne U.K. Pharmacokinetics and metabolism of selegiline. Acta Neurol. Scand. Suppl. 1989, 126:93-99.
22. Heinonen E.H., Anttila M.I., Lammintausta R.A. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 1994, 56:742-749.
23. Hornykiewicz O. Dopamine and Parkinson's disease. A personal view of the past, the present, and the future. Adv. Neurol. 2001, 86:1-11.
24. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov. Disord. 2002, 17:501-508.
25. Jarrott B., Vajda F.J. The current status of monoamine oxidase and its inhibitors. Med. J. Aust. 1987, 146:634-638.
26. Jenei V., Zor K., Magyar K., Jakus J. Increased cell-cell adhesion, a novel effect of R-(-)-deprenyl. J. Neural Transm. 2005, 112:1433-1445.
27. Johnston J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 1968, 17:1285-1297.
28. Kalász H., Kerecsen L., Knoll J., Pucsok J. Chromatographic studies on the binding, action and metabolism of (-)-deprenyl. J. Chromatogr. 1990, 499:589-599.
29. Katagi M., Tatsuno M., Miki A., Nishikawa M., Nakajima K., Tsuchihashi H. Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 2001, 759:125-133.
30. Katagi M., Tatsuno M., Tsutsumi H., Miki A., Kamata T., Nishioka H., Nakajima K., Nishikawa M., Tsuchihashi H. Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man. Xenobiotica 2002, 32:823-831.
31. Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech. Ageing Dev. 1988, 46:237-262.
32. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 1972, 5:393-408.
33. Knoll J., Ecseri Z., Kelemen K., Nievel J., Knoll B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmacodyn. Ther. 1965, 155:154-164.
34. Knoll J., Vizi E.S., Somogyi G. Phenylisopropylpropanylamine (E-250), a monoamine oxidase inhibitoe antagonizing the effects of tyramine. Arzneimittelforschung 1968, 18:109-112.
35. Langston J.W. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology 1990, 40(Suppl.):61-66. discussion 67-69.
36. Lengyel J., Magyar K., Hollósi I., Bartók T., Báthori M., Kalász H., Fürst S. Urinary excretion of deprenyl metabolites. J. Chromatogr. A 1997, 762:321-326.
37. Magyar K. Pharmacology of monoamine oxidase type-B inhibitors. Inhibitors of Monoamine Oxidase B, Pharmacology and Clinical Use in Neurodegenerative Disorders 1993, 125-143. Birkhauser Verlag, Basel. I. Szelényi (Ed.).
38. Magyar K. Behaviour of (-)-deprenyl and its analogues. J. Neural Transm. Suppl. 1994, 41:167-175.
39. Magyar K., Szende B. The neuroprotective and neuronal rescue effect of (-)-deprenyl. Handbook of Experimental Pharmacology 2000, 457-472. Springer-Verlag, Heidelberg. R.G. Cameron, G. Feuer (Eds.).
40. Magyar K., Szende B. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 2004, 25:233-242.
41. Magyar K., Szüts T. The fate of (-)-deprenyl in the body-preclinical studies. Proceedings of the International Symposium on (-)-Deprenyl, Jumex 1982, 25-31. Chinoin, Budapest. R. Szebeni (Ed.).
42. Magyar K., Tóthfalusi L. Pharmacokinetic aspects of deprenyl effects. Pol. J. Pharmacol. Pharm. 1984, 36:373-384.
43. Magyar K., Vizi E.S., Ecseri Z., Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol. Acad. Sci. Hung. 1967, 32:377-387.
44. Magyar K., Ecseri Z., Bernáth G., Sátory É., Knoll J. Structure-activity relationship of selective inhibitors of MAO-B. Monoamine Oxidases and Their Selective Inhibitors 1980, 11-21. Pergamon Press, Budapest. K. Magyar (Ed.).
45. Magyar K., Szende B., Lengyel J., Tekes K. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research. J. Neural Transm. Suppl. 1996, 48:29-43.
46. Magyar K., Szende B., Lengyel J., Tarczali J., Szatmáry I. The neuroprotective and neuronal rescue effects of (-)-deprenyl. J. Neural Transm. Suppl. 1998, 52:109-123.
47. Magyar K., Pálfi M., Tábi T., Kalász H., Szende B., Szöko{double acute} É. Pharmacological aspects of (-)-deprenyl. Curr. Med. Chem. 2004, 11:2017-2031.
48. Magyar K., Szatmáry I., Szebeni G., Lengyel J. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. J. Neural Transm. 2007, (Suppl.):165-173.
49. Magyar K., Szende B., Jenei V., Tabi T., Palfi M., Szoko E. R-deprenyl: pharmacological spectrum of its activity. Neurochem. Res. 2010, 35:1922-1932.
50. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin. Pharmacokinet. 1997, 33:91-102.
51. Mahmood I., Peters D.K., Mason W.D. The pharmacokinetics and absolute bioavailability of selegiline in the dog. Biopharm. Drug Dispos. 1994, 15:653-664.
52. Mahmood I., Marinac J.S., Willsie S., Mason W.D. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers. Biopharm. Drug Dispos. 1995, 16:535-545.
53. Natoff I.L. Cheese and monoamine oxidase inhibitors. Interactions in anaesthetised cats. Lancet 1964, 1:532-533.
54. Oreland L., Hallman J., Damberg M. Platelet MAO and personality-function and dysfunction. Curr. Med. Chem. 2004, 11:2007-2016.
55. Parnham M. The history of l-deprenyl. Inhibitors of Monoamine Oxidase B, Pharmacology and Clinical Use in Neurodegenerative Disorders 1993, 237-251. Birkhauser Verlag, Basel. I. Szelényi (Ed.).
56. Qin F., Shite J., Mao W., Liang C.S. Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. Eur. J. Pharmacol. 2003, 461:149-158.
57. Reynolds G.P., Elsworth J.D., Blau K., Sandler M., Lees A.J., Stern G.M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 1978, 6:542-544.
58. Ricci A., Mancini M., Strocchi P., Bongrani S., Bronzetti E. Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp. Clin. Res. 1992, 18:163-171.
59. Riederer P., Youdim M.B. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J. Neurochem. 1986, 46:1359-1365.
60. Riederer P., Lachenmayer L., Laux G. Clinical applications of MAO-inhibitors. Curr. Med. Chem. 2004, 11:2033-2043.
61. Rohatagi S., Barrett J.S., DeWitt K.E., Morales R.J. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm. Drug Dispos. 1997, 18:567-584.
62. Rohatagi S., Barrett J.S., McDonald L.J., Morris E.M., Darnow J., DiSanto A.R. Selegiline percutaneous absorption in various species and metabolism by human skin. Pharm. Res. 1997, 14:50-55.
63. Schachter M., Marsden C.D., Parkes J.D., Jenner P., Testa B. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J. Neurol. Neurosurg. Psychiatry 1980, 43:1016-1021.
64. Shih J.C., Chen K. Regulation of MAO-A and MAO-B gene expression. Curr. Med. Chem. 2004, 11:1995-2005.
65. Shin H.S. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab. Dispos. 1997, 25:657-662.
66. Sugiura M., Kato R. Reduction of tertiary amine N-oxides by rat liver mitochondria. J. Pharmacol. Exp. Ther. 1977, 200:25-32.
67. Szebeni G., Lengyel J., Székács G., Magyar K., Gaál J., Szatmári I. Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl-deprenyl in pig plasma. Acta Physiol. Hung. 1995, 83:135-141.
68. Szende B. Cell proliferation and cell death in relation to dose of various chemical substances. Monoamine Oxidase Inhibitors and Their Role in Neurotransmission 2004, 133-140. Medicina, Budapest. T. Török, I. Klebovich (Eds.).
69. Szende B., Magyar K., Szegedi Z. Apoptotic and antiapoptotic effect of (-)-deprenyl and (-)-desmethyl-deprenyl on human cell lines. Neurobiology (Bp.) 2000, 8:249-255.
70. Szende B., Bokonyi G., Bocsi J., Kéri G., Timár F., Magyar K. Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. J. Neural Transm. 2001, 108:25-33.
71. Szende B., Barna G., Magyar K. Cytoprotective effect of (-)-deprenyl, (-)desmethyl-deprenyl and (-)deprenyl-N-oxide on glutathione depleted A-2058 melanoma cells. J. Neural Transm. 2010, 117:695-698.
72. Szöko{double acute} É., Magyar K. Chiral separation of deprenyl and its major metabolites using cyclodextrine-modified capillary zone electrophoresis. J. Chromatogr. A 1995, 709:157-162.
73. Szöko{double acute} É., Tábi T., Borbás T., Dalmadi B., Tihanyi K., Magyar K. Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. Electrophoresis 2004, 25:2866-2875.
74. Taavitsainen P., Anttila M., Nyman L., Karnani H., Salonen J.S., Pelkonen O. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol. Toxicol. 2000, 86:215-221.
75. Tarjányi Z., Kalász H., Szebeni G., Hollosi I., Báthori M., Fürst S. Gas-chromatographic study on the stereoselectivity of deprenyl metabolism. J. Pharm. Biomed. Anal. 1998, 17:725-731.
76. Tatton W.G., Chalmers-Redman R.M. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996, 47:S171-S183.
77. Tatton W.G., Ju W.Y., Holland D.P., Tai C., Kwan M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 1994, 63:1572-1575.
78. Tatton W.G., Wadia J.S., Ju W.Y., Chalmers-Redman R.M., Tatton N.A. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J. Neural Transm. Suppl. 1996, 48:45-59.
79. Tekes K., Tóthfalusi L., Gaál J., Magyar K. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol. J. Pharmacol. Pharm. 1988, 40:653-658.
80. Tharakan B., Whaley J.G., Hunter F.A., Smythe W.R., Childs E.W. (-)-Deprenyl inhibits vascular hyperpermeability after hemorrhagic shock. Shock 2010, 33:56-63.
81. Thyaga Rajan S., Felten D.L. Modulation of neuroendocrine-immune signaling by L-deprenyl and L-desmethyldeprenyl in aging and mammary cancer. Mech. Ageing Dev. 2002, 123:1065-1079.
82. Thyaga Rajan S., Quadri S.K. l-Deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors. Endocrine 1999, 10:225-232.
83. Thyaga Rajan S., Madden K.S., Stevens S.Y., Felten D.L. Inhibition of tumor growth by L-deprenyl involves neural-immune interactions in rats with spontaneously developing mammary tumors. Anticancer Res. 1999, 19:5023-5028.
84. Thyaga Rajan S., Madden K.S., Stevens S.Y., Felten D.L. Anti-tumor effect of L-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogen-induced mammary tumors. J. Neuroimmunol. 2000, 109:95-104.
85. Tipton K.F., Boyce S., O'Sullivan J., Davey G.P., Healy J. Monoamine oxidases: certainties and uncertainties. Curr. Med. Chem. 2004, 11:1965-1982.
86. Tolosa E., Katzenschlager R. Pharmacologic management of Parkinson's disease. Parkinson's Disease and Movement Disorders 2007, 110-145. Lippincott, Williams and Wilkins, Philadelphia. J. Jankovic, E. Tolosa (Eds.).
87. Toronyi E., Hamar J., Magyar K., Szende B. Antiapoptotic effect of (-)-deprenyl in rat kidney after ischemia-reperfusion. Med. Sci. Monit. 2002, 8:BR65-BR68.
88. Valoti M., Fusi F., Frosini M., Pessina F., Tipton K.F., Sgaragli G.P. Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl. Eur. J. Pharmacol. 2000, 391:199-206.
89. Varga E., Tringer L. Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250" ). Acta Med. Acad. Sci. Hung. 1967, 23:289-295.
90. Wadia J.S., Chalmers-Redman R.M., Ju W.J., Carlile G.W., Phillips J.L., Fraser A.D., Tatton W.G. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J. Neurosci. 1998, 18:932-947.
91. Wecker L., James S., Copeland N., Pacheco M.A. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol. Psychiatry 2003, 54:1099-1104.
92. Whaley J.G., Tharakan B., Smith B., Hunter F.A., Childs E.W. (-)-Deprenyl inhibits thermal injury-induced apoptotic signaling and hyperpermeability in microvascular endothelial cells. J. Burn Care Res. 2009, 30:1018-1027.
93. Youdim M.B., Finberg J.P. Monoamine oxidase B inhibition and the "cheese effect" J. Neural Transm. Suppl. 1987, 25:27-33.
94. Youdim M.B., Weinstock M. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech. Ageing Dev. 2002, 123:1081-1086.
95. Youdim M.B., Gross A., Finberg J.P. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol. 2001, 132:500-506.
96. Zeller E.A., Barsky J. In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine. Proc. Soc. Exp. Biol. Med. 1952, 81:459-461.